Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

There are a number of catalysts on the horizon for global pharma stocks, but Jefferies has dialed back expectations for a number of stocks in the space. In a new report, analyst Jeffrey Holford has updated the firm’s outlook and price targets for the biggest names in the pharma space.

Despite lowering a number of price targets, Jefferies is excited about the potential for top pick AbbVie Inc (NYSE: ABBV).

“We expect that the PTAB decision whether or not to institute IPR on the CHRS challenge to ABBV’s ‘135 RA closing patent will be one of the most significant catalysts in the near future,” Holford explained.

Related Link: User Questions When Bill Ackman Had Access To Valeant Earnings

Jefferies predicts roughly a $9/share gain for AbbVie’s stock in the case of denial and a $3/share decline in the case of institution.

Jefferies maintains a Buy rating and $90 price target for AbbVie.

It's Not All About AbbVie

In addition, the firm has reduced price targets for the following U.S.-listed stocks:

• Abbott Laboratories (NYSE: ABT): to $44
• Eli Lilly and Co (NYSE: LLY): to $100
• Johnson & Johnson (NYSE: JNJ): to $108)

Jefferies also upped price targets for these names:

• Bristol-Myers Squibb Co (NYSE: BMY): to $76
• Pfizer Inc (NYSE: PFE): to $41)

Jefferies is currently most bullish on Buy rated names AbbVie, Abbott, Eli Lilly, Novartis AG (ADR) (NYSE: NVS), Pfizer, Roche Holding Ltd. (ADR) (OTC: RHHBY) and Zoetis Inc (NYSE: ZTS).

Finally, Holford sees the pharma M&A environment “heating up” and believes that a number of the big players are likely interested in Medivation Inc (NASDAQ: MDVN).

Disclosure: The author holds no position in the stocks mentioned.